Hypertension. 1995;25:663-673
(Hypertension. 1995;25:663-673.)
© 1995 American Heart Association, Inc.
The Renal Medulla and Hypertension
Allen W. Cowley, Jr;
David L. Mattson;
Shanhong Lu;
Richard J. Roman
From the Department of Physiology, Medical College of Wisconsin,
Milwaukee.
Correspondence to Allen W. Cowley, Jr, PhD, Department of Physiology, Medical College of Wisconsin, 8701 Watertown Plank Rd, PO Box 26509, Milwaukee, WI 53226-0509.
 |
Abstract
|
|---|
Abstract We review evidence supporting the conclusion that
renal
dysfunction underlies the development of all forms of
hypertension
in humans and experimental animals. Indexes of global
renal
function are generally normal in the early stages of most genetic
forms
of hypertension, but renal function is clearly impaired in
long-established
hypertension. Studies in our laboratory over the past
decade
summarized below have established that the renal medulla plays
an
important role in sodium and water homeostasis and in the long-term
control
of arterial pressure. Development of implanted optical fibers
for
measurement of cortical and medullary blood flows with
laser-Doppler
flowmetry and techniques for delivery of vasoactive
compounds
into the medullary interstitial space enabled us to examine
determinants
of medullary flow (nitric oxide, atrial natriuretic
peptides,
kinins, eicosanoids, vasopressin, renal sympathetic nerves,
etc).
We have shown in spontaneously hypertensive rats that the initial
changes
of renal function begin as a reduction of medullary blood flow
in
the absence of changes of cortical flow. Long-term medullary
interstitial
infusion of captopril, which preferentially increased
medullary
blood flow, resulted in a lowering of arterial pressure. In
normal
Sprague-Dawley rats, selective reduction of medullary
flow with
medullary interstitial or intravenous infusion of small
amounts
of
NG-nitro-
L-arginine methyl
ester resulted in hypertension.
These and other studies we review show
that although blood flow
to the inner renal medulla comprises less than
1% of the total
renal blood flow, changes in flow to this region can
have a
major effect on sodium and water homeostasis and on the
long-term
control of arterial blood pressure.
Key Words: kidney medulla hypertension, renal laser-Doppler flowmetry captopril
 |
Introduction
|
|---|
The studies in our laboratory that have
focused on the renal
medulla in hypertension evolved from the concept
that the kidney
plays a dominant role in the long-term control of
arterial pressure
based on the pressure-natriuresis
response.
1 2 By way of introduction
to our recent studies
of renal medullary blood flow, it is appropriate
to first explain why
we have focused our efforts so heavily
on the study of renal function.
It is now nearly 30 years since
Guyton and associates
2
first proposed that if an increase in
arterial pressure could produce
sustained elevations in urine
flow and sodium excretion through the
mechanism of pressure
diuresis, then this system would have infinite
gain for the
long-term control of arterial pressure by regulating blood
volume.
According to this theory, which is represented in
Fig 1
, whenever
arterial pressure is elevated,
activation of pressure natriuresis
would promote the excretion of
sodium and water until blood
volume is reduced sufficiently to return
arterial pressure to
control levels. Hypertension could only develop
when something
impairs the excretory ability of the kidney and shifts
the relationship
between sodium excretion and arterial pressure toward
higher
pressures. Although the kidney is the final common pathway in
the
long-term control of pressure, this hypothesis in no way presumes
that
the underlying abnormality in hypertension is intrinsic to the
kidney.
Indeed, abnormalities in the function of brain, endocrine
organs,
or the vasculature that alter the transmission of pressure to
the
kidney and/or disturb the neural and humoral control of sodium
and
water excretion in many instances underlie the resetting
of the
pressure-natriuresis relationship in various models of
hypertension.

View larger version (24K):
[in this window]
[in a new window]
|
Figure 1. Schematic shows the relationship between arterial
pressure and renal function in normal and hypertensive animals. When
arterial pressure is elevated, pressure natriuresis would result in the
excretion of sodium and water until blood volume is decreased enough to
return arterial pressure to control levels. The relationship between
sodium excretion and arterial pressure is blunted or shifted to a
higher pressure in every hereditary and experimental model of
hypertension yet studied. SHR indicates spontaneously hypertensive
rats; Dahl S, Dahl salt-sensitive rats; TGR, transgenic rats; RRM,
reduced renal mass; AII, angiotensin II; DOCA, deoxycorticosterone
acetate; and ALDO, aldosterone.
|
|
An enormous amount of accumulated data supports the view that renal
dysfunction underlies the development of all forms of hypertension in
humans and experimental animal models. These results can be subdivided
into five major lines of experimental evidence. (1) The induction of
all experimental models of hypertension involves some maneuver that
reduces the ability of the kidney to excrete sodium and water at normal
levels of arterial pressure. This includes Goldblatt
hypertension3 (renal artery stenosis), coarctation of the
aorta, mineralocorticoid models of hypertension (administration of
aldosterone or desoxycorticosterone),4 5 surgical
reduction of renal mass,6 perinephritic models of
hypertension, and long-term infusion of vasoconstrictors such as
angiotensin II (Ang II),7 8 9 vasopressin,10
and norepinephrine11 (the latter will produce sustained
hypertension only when infused intrarenally). (2) In humans and in all
of the genetic rat models of hypertension studied to dateincluding
spontaneously hypertensive rats (SHR),12 Dahl
salt-sensitive rats,13 Lyon hypertensive
rats,14 and even transgenic renin gene
rats15 the pressure-natriuresis response is blunted and
reset toward higher pressures. (3) All of the effective
antihypertensive drugs studied to date have actions that promote the
excretion of sodium and water and shift the pressure-natriuresis
relationship back to control. These drugs include converting enzyme
inhibitors,16 17 Ang II receptor blockers,18
diuretics, vasodilators,17 and calcium channel
blockers.19 (4) Studies by Hall et al4 7 10
have indicated that when renal excretory function is impaired by
administration of sodium- and water-retaining hormones such as Ang
II,7 aldosterone,4 or arginine vasopressin
(AVP),10 a rise in renal perfusion pressure is absolutely
essential to restore fluid and electrolyte balance. If renal perfusion
pressure is servocontrolled at normal levels, the animals will continue
to retain salt and water and develop malignant
hypertension.4 7 10 Similarly, Cowley and associates
(Krieger and Cowley20 and Cowley et al21 )
have shown that servocontrolling of body fluid volume by adjusting
fluid intake to match changes in sodium excretion can prevent the
development of hypertension produced by long-term administration of
vasoconstrictors such as Ang II20 and AVP.21
(5) Finally, renal transplantation studies in humans and in all of the
genetic rat models of hypertension yet studied indicate that blood
pressure follows the kidney; that is, transplantation of a hypertensive
kidney into a normotensive rat raises arterial pressure, and
transplantation of a normotensive kidney into a hypertensive rat
reduces arterial pressure. This includes studies in SHR,22
Dahl salt-sensitive,23 24 Milan,25 and
Prague26 genetic models of hypertension.
Despite this overwhelming body of evidence, the view that renal
dysfunction underlies the development of all forms of hypertension in
humans and experimental animals is not universally accepted. Many if
not most investigators believe that the changes in renal function are a
consequence of the hypertension rather than the primary basis of the
disease. An absence of a fundamental understanding of the mechanism of
pressure natriuresis for many years led to uncertainty as to whether
this mechanism could respond in a manner that would enable it to serve
as the long-term controller of sodium excretion. For this reason, we
have made considerable efforts to better understand this mechanism. It
had long been apparent that pressure natriuresis occurred in the
absence of an obvious intrarenal signal, because renal blood flow
(RBF), glomerular filtration rate (GFR), and pressure in the
peritubular capillaries were well autoregulated. These observations led
us to focus our attention on the possible role that changes in the
renal medullary hemodynamics may play in this response. In a series of
studies that has spanned the last decade, we found that pressure
natriuresis is indeed associated with increases in blood flow and
pressure in the vasa recta capillaries in the inner medulla of the
kidney. The lack of autoregulation in the medullary circulation results
in a parallel increase in renal interstitial pressure and loss of the
medullary osmotic gradient. These events together lead to inhibition of
sodium reabsorption in the proximal tubule and loop of Henle,
particularly in juxtamedullary nephrons, and account for the bulk of
the pressure-natriuresis response. This proposed mechanism is
attractive because it fulfills the requirement that pressure
natriuresis must occur via a nonadaptive mechanism in order to serve as
a long-term controller of arterial pressure. Moreover, we and others
have found that medullary blood flow and the sensitivity of the
pressure-natriuresis response is regulated by a variety of paracrine
and humoral factors known to play an important role in the control of
renal function and arterial pressure, including Ang II, kinins,
prostaglandins, atrial natriuretic peptide (ANP), and nitric oxide
(NO).27
 |
Reason for Studying the Medullary Circulation in Hypertension
|
|---|
In many experimental models of hypertension, there is no reason
to
believe that changes in blood flow to the renal medulla participate
in
the resetting of the pressure-natriuresis relationship (Fig
1
). For
example, immediately after renal artery stenosis (Goldblatt
hypertension),
it is clear that pressure and flow throughout the kidney
are
compromised. Similarly, in reduced renal mass, renoprival, and
perinephric
models of hypertension, it is obvious that global
reductions
in RBF and GFR are responsible for the reduced renal
excretory
capacity. In the endocrine models of hypertension produced by
exogenous
administration of sodium- and water-retaining hormones such
as
Ang II, aldosterone, or deoxycorticosterone acetate, the resetting
of
the pressure-natriuresis relationship can largely be attributed
to
enhanced tubular reabsorption of sodium and water. So even
if medullary
blood flow is reduced in these models of hypertension,
such reductions
are not necessary to explain the rise of arterial
pressure.
It is also apparent that renal functional abnormalities exist in all of
the genetic models of hypertension, as demonstrated by the shift of the
pressure-natriuresis-diuresis relationships to higher pressures in
SHR,12 28 Lyon hypertensive rats,14 Dahl
salt-sensitive rats,13 and transgenic rats overexpressing
the mouse Ren-2 gene.15 However, the nature of
the renal dysfunction in these forms of hypertension, as in human
essential hypertension, has not been apparent. RBF and GFR are similar
in SHR and normotensive rat strains12 29 before and during
the development of hypertension. This is also the case early in the
development of human essential hypertension.30 31 32 In these
situations, which represent most hereditary and clinical
hypertension, it was reasonable to suspect that more subtle changes in
renal tubular or vascular function contributed to the resetting of
renal function.
For these reasons, we explored the possibility that alterations
of renal medullary blood flow might be responsible for the shift in the
pressure-diuresis relationship toward higher pressure in SHR. The first
convincing evidence that medullary blood flow was indeed reduced in
hypertension was obtained with the use of laser-Doppler flowmetry, as
described below. These studies indicated that medullary blood flow was
reduced before the development of hypertension in
SHR.28 33 Further studies revealed that the reduction in
medullary flow in SHR was related to enhanced vascular tone in afferent
arterioles of juxtamedullary nephrons.34 These studies
confirmed earlier work by Ganguli et al35 indicating that
papillary blood flow is reduced in SHR. They also were consistent with
the original studies by Muirhead,36 who suggested that an
impaired release of antihypertensive lipids (medullipins) from
interstitial cells of the medulla may contribute to the development of
hypertension in SHR.
Although our studies suggested that reductions of medullary blood flow
might be responsible for the development of hypertension in the SHR,
this type of experiment could not establish cause-and-effect
relationships. Therefore, we directed our efforts toward developing a
method whereby we could selectively alter medullary blood flow
independent of changes of renal cortical blood flow and systemic
vascular resistance to determine whether a primary reduction in
medullary flow is sufficient to produce hypertension. Related to this
goal, we also had to develop methods to chronically measure cortical
and medullary blood flow in unanesthetized rats. The remainder of this
review describes the studies carried out in our laboratory over the
last 3 years to examine the hypothesis that a primary reduction in
medullary blood flow is sufficient to produce hypertension, whereas
increases in medullary blood flow can lower arterial pressure.
 |
Measurement of Medullary Blood Flow With the Use of Laser-Doppler
Flowmetry
|
|---|
Testing concepts regarding the role of the renal medulla in
hypertension
has proved to be challenging because blood flow to the
inner
medulla accounts for less than 1% of total RBF. Few people tried
to
study medullary blood flow throughout the late 1970s and 1980s
because
it had become apparent that the techniques available for the
study
of this circulation were fraught with difficulties and probably
invalid.
37 38 39 These techniques included measurement of the
clearance
of diffusible indicators (H
2,
85Kr,
133Xe, heat), measurement
of albumin or
red blood cell accumulation in the papilla, and
radiolabeled
microspheres. Blood flow in the vasa recta capillaries
at the tip of
the papilla of immature rats could be surgically
exposed and studied
with the use of fluorescent videomicroscopy.
38 39 This
technique has been criticized, however, because removal
of the ureter
itself alters papillary blood flow by stimulating
the release of
prostaglandins. So each of these techniques had
problems, and most of
them also required anesthesia, surgery,
exposure of the kidney, and
death of the animal. None of these
methods could provide continuous
measurements of medullary flow
or could be adapted for repeated use in
conscious animals.
37 38
In the early 1980s, Roman and coworkers13 40 41 began to
explore the use of laser-Doppler flowmetry to measure changes in blood
flow in the renal cortex and tip of the exposed papilla of anesthetized
rats. These studies yielded important new information indicating that
papillary blood flow increased after elevations in renal perfusion
pressure. Remarkably, the circulation of the inner medulla failed to
autoregulate blood flow. These responses could even be demonstrated in
young Munich Wistar rats in which the optical probe could be used to
measure papillary blood flow without exposure of the renal
papilla.42
A further refinement of the laser-Doppler technique that has since
evolved in our laboratory now allows us to chronically implant small
optical fibers into various regions of the kidney for simultaneous
measurement of cortical and medullary blood flows in conscious rats
under a variety of experimental conditions.43 44 45 As
illustrated in Fig 2, the 0.5-mm-diameter fibers
connected to an external probe are implanted to various depths in the
renal cortex and medulla of the kidney through a small hole made in the
renal capsule with the use of a 25-gauge needle. Implantation of these
fibers results in minimal bleeding in the rat and has no effect on RBF,
GFR, urine concentrating ability, or sodium and water excretion.
Histological damage is confined to within 200 µm of the fiber track,
and no disruption has been observed to the microcirculatory region
beyond the tip of the implanted fiber where flow is determined.

View larger version (0K):
[in this window]
[in a new window]
|
Figure 2. Photomicrograph shows the distribution of
[14C]clentiazem after its infusion into the renal
medullary interstitium of a rat kidney. The illustrations show the
position of the interstitial catheter used for compound delivery into
the renal medulla and the position of the two optical fibers used to
measure outer cortical blood flow and outer medullary blood flow.
|
|
All of the methods previously used to measure regional blood flow in
the kidney have severe limitations, so direct validation of the
laser-Doppler technique for measurement of tissue blood flow in the
kidney has been a problem. However, a number of comparisons have been
made which indicate that implanted optical fibers can provide reliable
measurements of changes of regional blood flow in kidney, albeit not in
absolute flow units. Specifically, changes of cortical blood flow
measured with implanted fibers in the superficial cortex closely
followed changes observed in whole-kidney blood flow measured with an
electromagnetic flowmeter.43 Changes of inner medullary
blood flow measured with an implanted fiber closely correlate to
changes in papillary blood flow measured with an external probe focused
on the exposed papilla of the rat43 or to changes in blood
flow in vasa recta capillaries measured with
videomicroscopy.46 The most direct validation of
laser-Doppler flowmetry for the measurement of papillary blood flow in
the rat compared the laser-Doppler flow signal with the rate of
accumulation of 51Cr-labeled erythrocytes in the
papilla.41 In this study, the laser-Doppler signal was
linearly related and highly correlated (r=.92) to red blood
cell flow into the papilla.
The use of acutely implanted fibers has recently enabled us to confirm
the original observations by Roman et al40 showing that
medullary blood flow is not autoregulated as well as cortical flow in
volume-expanded rats. The use of multiple optical fibers enabled
simultaneous determination of changes in blood flow in the inner and
outer medullas as well as the superficial and inner
cortices33 in response to changes in perfusion pressure.
These studies showed that as renal perfusion pressure was increased
above 100 mm Hg, total RBF, superficial cortical blood flow, and deep
cortical blood flow were all very well autoregulated. In contrast,
blood flow to the inner and outer medullas were autoregulated poorly in
volume-expanded rats. In hydropenic animals in which the plasma levels
of AVP are high and the renin-angiotensin system is activated,
medullary blood flow does not rise when renal arterial pressure is
increased above normal levels. That is, blood flow in the medulla is
autoregulated and the pressure-natriuresis relationship markedly
attenuated. The mechanism responsible for altering medullary flow and
the sensitivity of pressure natriuresis in hydropenic versus
volume-expanded rats is under intense investigation in our laboratory
but remains to be defined.
 |
Development of Techniques for the Infusion of Vasoactive Compounds
Into the Renal Medulla
|
|---|
For the evaluation of the consequences of selective alterations
of
medullary blood flow on the long-term control of arterial
pressure,
special techniques had to be developed that enabled
the delivery of
vasoactive agents directly into the renal medulla
of the
rat.
47 These techniques were first used in acute
anesthetized
rats studies and later adapted for the continuous
long-term
infusion of compounds into the renal medulla for
weeks.
45 48 49 Renal interstitial catheters made of
polyethylene and with
a tip diameter extruded to 100 µm were inserted
into the
white inner medulla and compounds continuously infused into
the
medullary interstitium at a rate of 5 to 10 µL/min. Substances
infused
into this region of the kidney are selectively accumulated
because
of the efficient countercurrent exchanger in the vasa recta
circulation.
As shown in Fig 2
, infusion of the radiolabeled
(
14C) calcium
antagonist clentiazem for 20 minutes resulted
in the distribution
of more than 92% of the total radioactivity in the
infused kidney
to the medulla (outer zone plus inner zone plus
papilla). The
total radioactivity retained in the infused kidney was 47
times
that found in the contralateral kidney.
47
This technique has enabled us to deliver vasoactive agents in the
medulla to selectively alter medullary vascular tone both acutely
(hours) and chronically (weeks), as determined by laser-Doppler
flowmetry. As summarized below, a number of mechanistically different
vasoconstrictor and vasodilator agents now have been infused into the
renal medulla to determine the effects of preferential changes of
papillary blood flow on sodium and water excretion as well as the
long-term control of arterial pressure.
 |
Influence of NO on Medullary Blood Flow, Pressure Natriuresis, and
the Long-term Control of Arterial Pressure
|
|---|
A number of studies have now indicated that NO plays a major
role
in the regulation of arterial pressure. Short-term inhibition
of
NO synthase is associated with a fall in RBF
50 51 52 53 and
GFR
50 51 54 and increases both preglomerular and
postglomerular
vascular resistance.
55 56 Long-term
administration of NO synthase
inhibitors produces sustained
hypertension
57 58 59 60 61 62 that appears to be related to a shift of
the renal pressure-natriuresis
relationship to higher levels of
arterial pressure.
52 55
We carried out studies to determine whether we could selectively alter
renal medullary blood flow and to determine the effects of such
modulation on sodium and water excretion. In these studies, infusion of
NG-nitro-L-arginine
(L-NAME, 120 µg/h) into the medullary interstitium produced a 24%
fall in papillary blood flow without altering cortical
flow.62 Renal interstitial pressure was reduced by 23%,
and sodium and water excretion was reduced by approximately 35%. GFR,
fractional sodium and water excretion, and total RBF were unchanged,
and no changes of systemic arterial blood pressure occurred in these
short-term, 1-hour studies. These results demonstrated for the first
time that NO is tonically active in the medullary circulation and that
changes in medullary blood flow alter sodium and water excretion (see
Fig 3). These observations were consistent with previous
reports that the renal papilla tissue slices have a greater capacity to
synthesize NO than the renal cortex in vitro56 and that
the vascular and tubular segments of the renal medulla have a large
capacity for producing NO.64

View larger version (15K):
[in this window]
[in a new window]
|
Figure 3. Line graph (left) shows changes in renal cortical
and papillary blood flows in response to infusion of
NG-nitro-L-arginine methyl
ester (L-NAME) at 120 µg/h into the renal medullary interstitium of
anesthetized normotensive rats. Bar graph (right) shows changes in
urine volume (UVol) and sodium excretion (UNaV) accompanying medullary
interstitial infusions of L-NAME in the infused left kidney and
noninfused contralateral kidney. *P<.05. (Data from Mattson
et al62 ; reprinted with permission from Cowley et
al.63 )
|
|
Other studies in our laboratory have also demonstrated an important
role for NO in mediating the effects of kinins on medullary blood flow.
Previous studies have suggested that bradykinin shifts the distribution
of renal blood65 66 67 to the renal medulla and promotes the
excretion of sodium and water.42 The influence of
endogenously produced kinins on medullary blood flow was determined by
assessing the effects of converting enzyme inhibitors and other
inhibitors of kinin degradation and by determining whether these
effects could be reversed with a kinin receptor
antagonist.42 68 Kininase II inhibition with enalaprilat
increased papillary blood flow by nearly 50%, and infusion of the
kinin antagonist returned papillary blood flow to control
levels.42 Outer cortical blood flow and arterial pressure
were not altered, and GFR was unchanged. Associated with the increase
of papillary flow, urine flow and sodium excretion
increased.42 69
We also carried out studies to examine the effects of infusion of
bradykinin directly into the medullary interstitium.69
Papillary blood flow increased by 20% during bradykinin infusion, and
total RBF, GFR, and renal interstitial hydrostatic pressure were
unaffected. Urine flow and sodium excretion increased by 100% to 120%
in the absence of changes in renal tubular or vascular function in the
contralateral kidney. Pretreatment of the medullary interstitium with
the NO inhibitor L-NAME blocked the effects of bradykinin on the
medullary circulation. L-NAME also blocked the effects of captopril on
papillary blood flow, whereas this effect was not blocked by
pretreatment of the rats with a cyclooxygenase
inhibitor.16 These studies show that the intrarenally
generated kinins may play an important role in the regulation of
medullary blood flow and that the effect of kinins on the medullary
circulation is mediated by an NO-dependent mechanism.
In these same studies, we also determined the role of NO on the
vasodilator effects of acetylcholine, demonstrating that medullary
infusion of acetylcholine at a dose of 200 µg/h produced increases in
medullary blood flow similar to those produced with bradykinin (34%),
with only small increases (13%) of cortical blood
flow.62
 |
Role of NO in Long-term Regulation of Medullary Blood Flow
|
|---|
Having obtained evidence in anesthetized rats for an
important
role of NO control of medullary blood flow, we turned our
attention
to studies designed to determine whether we could chronically
reduce
medullary blood flow and produce a sustained form of
hypertension.
Rats were instrumented with a catheter for long-term
L-NAME
infusion into the renal medulla, and optical fibers were
implanted
for measurement of changes in cortical and medullary blood
flows.
As summarized in Fig 4
, long-term L-NAME infusion
into the renal
medulla selectively reduced papillary blood flow by
nearly 30%.
45 This reduction was apparent as early as 2
hours after L-NAME
infusion was started and clearly preceded the rise
of mean arterial
pressure (MAP). The reduction of medullary flow was
maintained
throughout the experiment. Cortical blood flow was
unaltered.
After L-NAME infusion was stopped, blood flow in the renal
medulla
and arterial pressure gradually returned to control levels.
Sodium
excretion decreased significantly on the first day of L-NAME
infusion
and remained reduced throughout 5 days of drug infusion. MAP
rose
in parallel with the retention of sodium excretion. Negative
sodium
balance, which paralleled the return of arterial pressure to
control
levels, was seen after L-NAME infusion was stopped.

View larger version (17K):
[in this window]
[in a new window]
|
Figure 4. Line graphs show time course of changes in mean
arterial pressure (MAP), renal medullary blood flow (medullary flow
signal), and renal cortical blood flow (cortical flow signal) in
conscious, uninephrectomized Sprague-Dawley rats during renal
medullary interstitial infusion (r.i.) of
NG-nitro-L-arginine methyl
ester (L-NAME) for 5 days. Blood flow in the renal cortex and medulla
is represented by the raw voltage signal recorded from
optical fibers implanted in the kidney with the use of laser-Doppler
flowmetry. *P<.05 from third control day. (From Mattson et
al.45 )
|
|
These data demonstrate that NO plays an important role in the
regulation of blood flow in the renal medulla. Moreover, these studies
indicate that selective reductions of medullary blood flow can produce
a sustained elevation of arterial blood pressure. The rise of arterial
pressure could not be explained on the basis of a systemic action of
recirculated L-NAME because minimal systemic inhibition of NO synthase
was observed in these studies. Specific reductions in medullary blood
flow would be expected to increase the reabsorption of sodium in the
deep nephrons, especially in the loop of Henle,27 which
could explain the retention of sodium and hypertension. However,
removal of the inhibitory effects of endogenous NO on sodium transport
in the medullary collecting duct cannot be excluded as part of the
mechanism involved in the resetting of the pressure-natriuresis
relationship in this form of hypertension. Nevertheless, as discussed
below, we have observed a consistent relationship between changes in
medullary blood flow and the level of blood pressure with the use of a
variety of vasoactive compounds, some of which have no known action or
even opposite effects on tubular function. Thus, the common element in
our studies related to blood pressure appears to be changes of
medullary blood flow.
 |
Long-term Intravenous L-NAME Infusion
|
|---|
We have performed studies to determine the extent to which
changes
in renal medullary flow participate in the development of
hypertension
produced by long-term intravenous L-NAME
administration.
70 Intravenous L-NAME infusion produced
sodium and water retention
and a sustained elevation of blood pressure,
as expected. This
was accompanied by a preferential 22% fall in
medullary blood
flow, which remained at this level throughout the
experiment.
After L-NAME treatment was stopped, medullary blood flow
and
arterial pressure rapidly returned to control levels. The L-NAME
dose
chosen was low enough so that it had no effect on cortical blood
flow
throughout the study. The reduction of medullary flow and
development
of hypertension were associated with retention of sodium
and
water. Previous studies have assumed that systemic vasoconstriction
and
central neural actions were largely responsible for the development
of
hypertension produced by systemic blockade of NO synthase. However,
our
results indicate that changes in renal medullary blood flow
probably
are equally important in resetting the pressure-natriuresis
relationship,
which is essential. Taken together, the results of both
the
intrarenal and intravenous L-NAME infusion studies indicate
that in
the absence of measurable changes in RBF at the whole-kidney
level,
reductions of medullary flow alone are sufficient to
reset the
pressure-natriuresis relationship and promote sodium
retention and the
development of hypertension.
 |
Effects of Long-term Medullary Interstitial Infusion of a
V1 Agonist
|
|---|
The renal medullary circulation has long been thought to
play
an important role in maintaining the osmotic gradient, but the
possible
role of changes in medullary blood flow in determining maximal
urinary
concentrating ability has not been directly studied. Acutely
implanted
optical fibers enabled us recently to study the influence of
AVP
on medullary blood flow.
71 These studies, performed in
renal
denervated rats, also determined the relative contribution of
V
1 and V
2 receptors to the response to AVP.
Infusion of a V
1 receptor
agonist into the renal medulla
selectively reduced blood flow
in the outer medulla by 15% and to the
inner medulla by 35%.
Equimolar doses of AVP also decreased outer
medullary blood
flow by 15%, but the fall in inner medullary flow
(17%) was
significantly less than that observed with the
V
1 agonist. Stimulation
of V
2 receptors by
medullary interstitial infusion of the V
2 agonist
1-desamino-8-
D-AVP or infusion of AVP in rats pretreated
with
a V
1 receptor antagonist increased medullary blood
flow by 16%
and 27%, respectively. These studies demonstrate that AVP
has
two diametrically opposed actions on medullary blood flow resulting
from
stimulation of the V
1 and V
2 receptors.
Stimulation of V
2 receptors
attenuates the vasoconstrictor
actions of AVP and the V
1 receptor
on the medullary
circulation and likely accounts for the inability
of the endogenous
hormone to induce hypertension or sodium retention.
Given that infusion of the V1 agonist lowers
medullary blood flow, we then studied the long-term effects of such
infusion on arterial pressure. We found that the continuous intravenous
infusion of small doses of a specific V1 receptor agonist
produced sustained hypertension.72 Since it was evident
from our short-term studies in anesthetized rats71 that
this compound resulted in a significant reduction of medullary blood
flow, we undertook several studies to examine the role of
V1-mediated medullary vasoconstriction in long-term
arterial pressure control. In one of these studies, we were able to
prevent the development of hypertension produced by systemic infusion
of the V1 agonist by simultaneous administration of a
V1 receptor antagonist (equimolar amounts) into the renal
medulla.49 Moreover, as soon as the infusion of the
V1 antagonist into the renal medulla was discontinued, the
continued intravenous administration of the V1 agonist
produced systemic hypertension. These studies indicate that the renal
medullary vasoconstrictor actions of the systemically administered AVP
agonist were required to produce the hypertension.
As reported in the above study, infusion of the V1 agonist
in the renal medulla reduced inner medullary blood flow by 35% (see
above and Reference 7070 ). We performed studies to determine whether
infusion of the V1 agonist into the renal medulla alone was
sufficient to produce sustained hypertension.49 As shown
in Fig 5, we observed a sustained rise in MAP of nearly
20 mm Hg over the 14 days of the experiment. After infusion was
terminated, arterial pressure rapidly returned to the normal control
levels of 100 mm Hg. The same degree of hypertension was seen by renal
medullary infusion in renal denervated rats. Since renal medullary
infusion of AVP does not produce hypertension, it appears that
simultaneous stimulation of the V2 receptor in some way
modulates the hypertensive effects of the endogenous
hormone.49 72 Preliminary studies (A.W.C., unpublished
results, 1994) in five rats have indicated that medullary interstitial
infusion of these amounts of the V1 agonist results in a
sustained reduction of medullary blood flow in the complete absence of
changes in cortical flow over a period of at least 5 days.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 5. Line graph shows time course of changes in mean
arterial pressure (MAP) in conscious Sprague-Dawley rats
given a V1 agonist into the renal medulla (r.i.) for 14
days. *P<.05 from the final control day. (From
Szczepanska-Sadowska et al.49 )
|
|
Once again, the renal medullary vasoconstrictor actions of a compound
appear to account fully for the development of this model of
hypertension. Interestingly, we found no evidence of sodium retention
in these studies, which conforms to short-term observations in
anesthetized rats that medullary interstitial infusion of the
V1 agonist does not result in increased reabsorption of
filtered sodium.73 Nor did the long-term infusion of the
V1 agonist systematically lead to volume retention or a
rise of plasma renin or aldosterone.49 72 Measurements of
systemic plasma levels of AVP during long-term infusions into the
medullary interstitial space (7 days) showed no changes in circulating
levels in the blood. Since AVP and the V1 agonist are
metabolized identically and can be measured by radioimmunoassay, this
indicated that recirculation of the infused compound does not account
for the rise of arterial pressure.
It is recognized that hypertension can occur in the absence of sodium
and water retention because sodium and water balance can be achieved
after renal excretory ability is impaired by a rapid rise of arterial
pressure that offsets the lower excretion rate through the
pressure-natriuresis-diuresis mechanism. Nevertheless, the mechanism
whereby medullary vasoconstriction led to the rise of arterial pressure
in these particular V1 agonist studies raises important
questions as to whether the rapid rise in arterial pressure seen in
these experiments was due to suppression of the release of a
vasodilator substance such as medullipin36 or the release
of an unidentified vasoconstrictor substance.
 |
Antihypertensive Effects of a Selective Increase of Medullary Blood
Flow in SHR
|
|---|
We and others
3 12 28 74 have shown that kidneys of
SHR require
a higher level of arterial pressure than kidneys of
normotensive
rats to excrete a given amount of sodium and water and
that
this is associated with a reduced papillary blood
flow.
12 19 33 As might be predicted from the reduction of
medullary blood
flow, parallel reductions of renal interstitial
hydrostatic
pressure for a given level of perfusion pressure were
observed.
19 74 Importantly, the relationship between
papillary blood flow
and renal perfusion pressure was shifted to a
higher pressure
level early in the development of hypertension. For
example,
a reduction in the slope of the pressure-natriuresis
relationship
was clearly evident in 3- to 4-week-old SHR compared with
age-matched
Wistar-Kyoto rats (WKY).
28 At this age, it is
difficult to
demonstrate a significant difference in MAP with
indwelling
catheters. Thus, the fall in papillary blood flow and the
resetting
of pressure natriuresis are probably not consequences of
preexisting
hypertension. Since the reduction in renal papillary blood
flow
is one of the earliest abnormalities in renal function that
occurs
during the development of hypertension in SHR, it appeared
that this
dysfunction might contribute to the resetting of the
pressure-natriuresis
relationship and the development of hypertension
in these animals.
Recently, we tested this concept by long-term infusion of captopril, a
potent medullary vasodilator, into the renal medullary interstitial
space of uninephrectomized SHR.48 As shown in Fig 6, this increased medullary blood flow by 40%, whereas
renal cortical blood flow remained unchanged throughout the 5 days of
medullary infusion of captopril. MAP fell 20 mm Hg while captopril was
infused, and this was associated with a negative sodium balance.
Medullary blood flow returned to control after captopril infusion, and
arterial pressure rebounded to levels that exceeded those seen at the
beginning of the study. In another rat group exposed to chronically low
and high levels of sodium intake during medullary interstitial
captopril infusion, it was seen that the chronic renal function curve
(the steady-state relationship between sodium excretion and MAP) was
shifted to a lower level of arterial pressure compared with that seen
in vehicle-treated SHR. Captopril infused intravenously at the same low
dose given into the renal medulla had no effect on arterial pressure.
This finding excluded the possibility that the antihypertensive effect
of captopril given into the renal medulla of SHR was due to
recirculation of the infused compound.

View larger version (17K):
[in this window]
[in a new window]
|
Figure 6. Line graphs show time course of changes in mean
arterial pressure (MAP), renal medullary flood flow (medullary flow
signal), and renal cortical blood flow (cortical flow signal) in
conscious spontaneously hypertensive rats receiving captopril into the
renal medulla (r.i.) for 5 days. *P<.05 from final control
day. (From Lu et al.48 )
|
|
These results provide the first direct evidence in unanesthetized rats
that the renal medulla plays an important role in the development of
hypertension in SHR. The reduction of arterial pressure in this model
once again demonstrates a striking parallelism with the increase in
medullary blood flow.
 |
Escape From Long-term Actions of ANP and Calcium Channel
Inhibitors
|
|---|
Several other studies carried out in our laboratory have
contributed
to our understanding of some of the determinants of
medullary
flow and their relationship to the long-term control of
arterial
pressure. In one of these studies, we evaluated the effects
of
the ANP atriopeptin III (APIII) on pressure natriuresis and
papillary
blood flow. Previous studies have demonstrated that
ANP can chronically
lower blood pressure without causing sodium
retention, indicating that
renal excretory function must be
reset in some way to enable sodium
balance to be achieved at
a lower renal perfusion
pressure.
74 Since our studies had shown
that changes in
renal medullary hemodynamics are associated
with the
pressure-natriuresis response, we first examined the
effects of APIII
on the renal response to changes in renal perfusion
pressure in
anesthetized rats.
76 We found that APIII infusion
altered
the relationships between the fractional excretion of
sodium and water
and renal perfusion pressure without producing
sustained alterations of
GFR or total RBF. APIII infusion also
produced a 15% increase of
papillary blood flow, whereas cortical
flow was not significantly
altered. In other studies, we found
that the natriuretic response to
APIII was associated with a
rise in renal interstitial pressure and a
marked increase in
the distal delivery of sodium.
62 76
Removal of the renal medulla
to prevent elevations in papillary blood
flow completely blocked
the changes in renal interstitial pressure and
the natriuretic
response to APIII.
77 These studies
suggested that small increases
of circulating ANP could influence the
long-term control of
arterial pressure by preferentially altering renal
medullary
hemodynamics, raising renal interstitial pressure, and
promoting
the elimination of sodium and water in the absence of changes
in
total RBF or GFR.
We have since carried out long-term studies infusing APIII (50 ng/kg
per minute) into the medullary interstitial space for 5 days in four
uninephrectomized Sprague-Dawley rats, as shown in Fig 7.78 MAP decreased 20 mm Hg from normal
control levels for the first 3 days of infusion but then began to
return toward control levels. At the end of the 5-day infusion period,
pressure had returned halfway (10 mm Hg) toward control levels.
Although we did not carry out daily measurements of medullary blood
flow in this study, the APIII dose used was the same as that found in
short-term studies to be sufficient to increase medullary blood flow
when infused into the renal medulla in the absence of changes of
cortical blood flow or MAP.

View larger version (18K):
[in this window]
[in a new window]
|
Figure 7. Line graph shows changes in mean arterial pressure
(MAP) in conscious, uninephrectomized Sprague-Dawley rats
(n=4) receiving an infusion of atriopeptin III (APIII) into the renal
medulla (r.i.) for 5 days. *P<.05 from final control day.
(From Lu.78 )
|
|
Short- and long-term studies with calcium antagonists also support an
important role of the medullary circulation in the long-term control of
arterial pressure. In one study, responses to intravenous nisoldipine
were compared in SHR and WKY.19 These studies showed that
papillary flow increased to a greater extent in SHR than in WKY and
normalized the pressure-natriuresis relationship between the SHR and
WKY. In another study, the effects of the calcium channel antagonist
diltiazem on papillary blood flow were evaluated.47
Studies were carried out to examine whether calcium antagonists would
increase renal medullary blood flow and shift the relationship between
sodium excretion, papillary blood flow, and renal perfusion pressure.
Infusion of diltiazem into the medullary interstitial space at a dose
that produced no significant changes of arterial pressure, total RBF,
or renal cortical blood flow47 increased papillary blood
flow by 26%, and this was associated with a 65% rise in sodium and
water excretion. GFR was unchanged after an initial rise during the
first 20 minutes of diltiazem infusion, whereas the fractional
excretion of sodium remained 80% above control values, paralleling the
changes in papillary blood flow that remained elevated for more than 1
hour after drug administration.
We then carried out long-term studies in which we infused diltiazem
chronically into the medullary interstitial space (100 µg/kg per
minute) of six uninephrectomized SHR.78 As observed with
captopril, MAP decreased by nearly 25 mm Hg from a control level of
165 mm Hg during the first day of infusion. However, this reduction
was not sustained, and after 5 days of medullary infusion of this
compound, arterial pressure returned to control levels. The diltiazem
dose chosen for this study was the same as that studied in normal
anesthetized rats (see above) and which increased papillary blood flow
by 26%.
These studies once again indicate that arterial pressure can be
chronically influenced by the dilation or constriction of the medullary
circulation. However, these results also demonstrate that as with many
control systems, counterregulatory systems exist that may allow for
escape from the primary or initial effects of certain stimuli. It is
evident that the mechanisms which regulate medullary blood flow and
deep nephron function are complex and likely involve interactions with
many of the other factors regulating sodium excretion. Depending on the
stimuli used to modulate blood flow to this region, it is evident that
different counterregulatory mechanisms such as activation of the
renin-angiotensin system or sympathetic nervous system secondary to
volume contraction could either reinforce or override the initial
response.
 |
Control of Medullary Blood Flow
|
|---|
The studies summarized above suggest that changes of renal
medullary
blood flow have the ability to influence the long-term
control
of arterial blood pressure. Specifically, it is clear that
blood
flow to this region is an important component of the
pressure-natriuresis
mechanism, which is of utmost importance in the
long-term control
of arterial pressure. As discussed in detail
elsewhere,
1 27 it is also evident that factors shown to
reduce medullary blood
flow are those that are commonly associated with
long-term elevations
of arterial pressure and salt-sensitive forms of
hypertension
(sympathetic nerve stimulation, cyclooxygenase inhibition,
kinin
antagonists, NO synthase inhibition, Ang II, and AVP).
Conversely,
the factors that increase medullary blood flow are those
which
have been often associated with the lowering of blood pressure
(ANP,
acetylcholine, prostaglandins, converting enzyme inhibitors,
bradykinin,
and calcium antagonists). The studies reviewed in the
preceding
sections extended these studies to determine the long-term
consequences
of changing medullary blood flow by manipulating some of
these
systems.
 |
Summary
|
|---|
The evidence summarized above establishes that the renal
medulla
plays an important role in sodium and water homeostasis and
in
the long-term control of arterial blood pressure. Many of
the
potentially important physiological and pathophysiological
determinants
of medullary blood flow, ranging from intrarenal
paracrine systems,
circulating hormones, and renal sympathetic
nerve activity, have been
characterized. Although blood flow
to the inner renal medulla comprises
less than 1% of the total
RBF, changes in blood flow to this region
can have an important
effect on the set point of the
pressure-natriuresis relationship
and thereby influence the long-term
control of arterial pressure.
Studies in SHR suggest that the initial
changes of renal function
begin as a subtle preferential reduction of
medullary blood
flow in the absence of more global changes in renal
hemodynamics
such as cortical flow, RBF, and GFR. Many studies have
shown
that with prolonged established hypertension, the renal
circulation
throughout the entire kidney eventually becomes involved
with
the development of generalized glomerular sclerosis and end-stage
renal
disease. Results of studies in which medullary blood flow was
preferentially
reduced by blockade of NO synthase or medullary infusion
of
AVP clearly demonstrate that reduction of medullary blood flow
alone
is sufficient to produce systemic hypertension. However,
considerable
work remains to find the genes and establish the
genetic abnormalities
that increase medullary vascular resistance
and promote the development
of hypertension in hereditary forms
of hypertension in humans and
genetic animal models such as
the SHR.
 |
Acknowledgments
|
|---|
This work was supported in part by grants HL-49219, HL-29587,
and
HL-36279 from the National Heart, Lung, and Blood Institute.
The
authors wish to thank Meredith Skelton for her review of
the manuscript
and Terri Harrington for her secretarial assistance.
 |
References
|
|---|
-
Cowley AW Jr. Long-term control of arterial blood
pressure. Physiol Rev. 1992;72:231-300. [Abstract/Free Full Text]
-
Guyton AC, Coleman TG, Cowley AW Jr, Scheel KW, Manning RD
Jr, Norman RA. Arterial pressure regulation: overriding dominance of
the kidneys. Am J Med. 1972;52:584-594. [Medline]
[Order article via Infotrieve]
-
Norman RA, Enobakhare JA, DeClue JW, Douglas BH, Guyton AC.
Arterial pressure-urinary output relationship in hypertensive rats.
Am J Physiol. 1978;234:R98-R103.
-
Hall JE, Granger JP, Smith MJ Jr, Prennan AJ. Role of renal
hemodynamics and arterial pressure in aldosterone `escape.'
Hypertension. 1984;6(suppl I):I-183-I-192.
-
Cowley AW Jr, Skelton MM, Merrill DC. Are hypertensive
effects of aldosterone, angiotensin, vasopressin, and norepinephrine
chronically additive? Hypertension. 1979;1:549-558. [Abstract/Free Full Text]
-
Douglas BH, Guyton AC, Langstrom JB, Bishop VS. Hypertension
caused by salt loading, II: fluid volume and tissue pressure changes.
Am J Physiol. 1964;207:669-671.
-
Hall JE, Granger JP, Hester RL, Coleman TG, Smith MJ Jr,
Cross RB. Mechanisms of escape from sodium retention during angiotensin
II hypertension. Am J Physiol. 1984;246:F627-F634. [Abstract/Free Full Text]
-
DeClue JW, Guyton AC, Cowley AW, Coleman TG, Norman RA, McCaa
RE. Subpressor angiotensin infusion, renal sodium handling, and
salt-induced hypertension in the dog. Circ Res. 1978;43:503-512. [Abstract/Free Full Text]
-
Mattson DL. Influence of Angiotensin II on the
Regulation of Intrarenal Blood Flow Distribution and Pressure
Natriuresis in the Rat. Milwaukee, Wis: Medical College of
Wisconsin; 1990. Dissertation.
-
Hall JE, Montani JP, Woods LL, Mizelle HL. Renal escape
from vasopressin: role of pressure diuresis. Am J
Physiol. 1986;250:F907-F916. [Abstract/Free Full Text]
-
Cowley AW Jr, Lohmeier TE. Changes in renal vascular
sensitivity and arterial pressure associated with sodium intake during
long-term intrarenal norepinephrine infusion in dogs.
Hypertension. 1979;1:549-558.
-
Roman RJ, Cowley AW Jr. Abnormal pressure-diuresis-natriuresis
response in spontaneously hypertensive rats. Am J
Physiol. 1985;248:F199-F205.
-
Roman RJ. Abnormal renal hemodynamics and pressure-natriuresis
relationship in Dahl salt-sensitive rats. Am J
Physiol. 1986;251:F57-F65.
-
Liu KL, Benzoni D, Sassard J. Prostaglandin H2/thromboxane A2
and renal function in Lyon hypertensive rat. <